Financials
Financial year 2025
In2Clinical from Boortmeerbeek, company number BE0781726958, closed financial year 2025 with a result of € -5,472 after tax. For that financial year In2Clinical recorded a gross margin of € -5,291 and equity of € 17,331. Compared with financial year 2024, the result moved from € 4,332 to € -5,472. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 17,331
▼ 24% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,472
▼ still € 4,332 profit in 2024
Profit after tax over the fiscal year.
€ 18,304
▼ 36% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 11,331.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 171
▼ 84% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,271
▼ 77% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 21,973 | € 5,759 | € -5,291 | ▼ € 11,049 |
| Profit after taxes | € 15,803 | € 4,332 | € -5,472 | ▼ € 9,804 |
| Equity | € 21,803 | € 22,803 | € 17,331 | ▼ 24% |
| Total debts | € 5,370 | € 10,168 | € 1,442 | ▼ 86% |
| Cash | € 20,539 | € 28,488 | € 18,304 | ▼ 36% |
| Retained profit | € 15,803 | € 16,803 | € 11,331 | ▼ 33% |
| Dividend | € 0 | € 3,332 | € 0 | ▼ 100% |
| Balance sheet total | € 27,173 | € 32,971 | € 18,773 | ▼ 43% |
Key figures of In2Clinical, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to In2Clinical?
What happened at In2Clinical in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 5,472 (▼ € 9,804 vs 2024). Source: NBB ↗
- New establishment in Boortmeerbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 15,803 profit in 2023 to € 5,472 loss in 2025.
Paid € 5,293 in corporate taxes since 2023.
Best year ever: 2023, with € 15,803 profit.
Paid out € 3,332 in dividends to the owners in total.
Management
Behind In2Clinical are Tom Hallaert, Kim Janssens, Carl Mees and Gitte Van Hoof.
Directors
According to the 2025 annual accounts
Tom Hallaert
Director
Kim Janssens
Director
Carl Mees
Director
Gitte Van Hoof
Director
Establishments
Establishment units
Physical locations of this company
Looikesstraat 2
3190 Boortmeerbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0781.726.958
- VAT number
- BE 0781.726.958
- Registered office
- Looikesstraat 2, 3190 Boortmeerbeek
- Names & denominations
- In2Clinical
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 February 2022
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie